title: Multifocal reversible epithelial dysplasia mimicking carcinoma in situ after conditioning therapy with busulfan and cyclophosphamide.
authors.forename: E
authors.initials: E
authors.lastname: Obermann
authors.forename: N
authors.initials: N
authors.lastname: Meidenbauer
authors.forename: R
authors.initials: R
authors.lastname: Zeltner
authors.forename: R
authors.initials: R
authors.lastname: Andreesen
authors.forename: A
authors.initials: A
authors.lastname: Reichle
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002066:Busulfan / Q000009:adverse effects*; D002278:Carcinoma in Situ / Q000473:pathology; D003520:Cyclophosphamide / Q000009:adverse effects*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D003937:Diagnosis, Differential; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000628:therapy*; D008942:Mitoxantrone / Q000008:administration & dosage; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage; D014182:Transplantation, Autologous; D002578:Uterine Cervical Dysplasia / Q000139:chemically induced* / Q000473:pathology*
chemical_list: D003561:Cytarabine; D003520:Cyclophosphamide; D008942:Mitoxantrone; D013866:Thioguanine; D002066:Busulfan; D003630:Daunorubicin